With advances in healthcare innovations, the association among medtech, big tech, and big pharma is becoming ever more complex. Although there are close interactions within these industries due to digital health, artificial intelligence, and advanced therapy, significant differences in strategies, cultures, and timelines make collaborations difficult. The panelists at LSI USA ’25 considered ways to better align companies across different industries and explained why strong collaborations are becoming critical for future healthcare innovations.
During the medtech summit, the experts discussed the successful approach medtech companies should take in partnership with tech and pharmaceutical companies while keeping their strategic goals intact.
Why medtech, Big Tech, and Big Pharma Think Differently
Innovation and risk-taking are distinct areas discussed across industries, and sectors differ in how they approach innovation and risk-taking.
The pharmaceutical industry requires extensive clinical evidence and long timelines due to the massive amount of money needed for large trials. It focuses on the need to understand mechanisms, scaling, and therapeutics.
Medical device companies have fast development timelines and small-scale clinical studies. Medical device companies usually focus on iterating their product rapidly and conducting human testing quickly to improve the product and cut down development costs.
Big tech companies approach the problem in another way. They tend to focus on scaling, data architecture, adoption, and growth platforms. They focus more on software performance and speed.
The Growing Importance of Evidence and Data
However, it was stressed during the medtech summit that the ability to generate evidence continues to be a major gap when compared to pharmaceuticals companies.
For medtech, there can be fast movement into clinics with less but sufficient evidence. In pharmaceuticals, there needs to be an extensive understanding of the mechanics and large-scale validation before any expansion of the program or partnership is considered.
It became apparent that understanding what makes the product effective can become as vital as the proof of its efficacy. The understanding will provide for expanding to more indications, as well as help to facilitate regulatory discussions.
One other area which continued to show up again is data. Now that AI is becoming increasingly prominent in the field of medicine, healthcare data can be seen as an asset.
The following realities regarding healthcare data have been identified:
- Fragmentation within healthcare systems
- Accessing data from outside sources is quite difficult
- Product-generated data becomes more important
- AI development requires large datasets
The companies should consider their data strategy a part of the main function.
Different Investors Bring Different Expectations
This discussion also touched on the significant differences in views among investors depending on whether they operate in medtech, pharma, and tech domains.
For example, as noted by panelists, medtech investors tend to be more patient due to the lengthy process of adopting devices, training physicians, and integrating the procedure.
Tech investors typically concentrate on quick development and growth in terms of scaling revenue and increasing the number of users following approval or product launch. Meanwhile, pharmaceutical investors care about clinical milestones more.
However, having investors from various industries on one board may result in conflicts due to such disparities. Yet, at the same time, panelists noted that such differences may stimulate more thoughtful strategies and help people view the problem from different angles.
During the summit, speakers emphasized the need for founders to handle these differences and manage them.
Why Communication Is Critical in Cross-Sector Partnerships
Communication is one thing that has been highlighted by panel members to determine success or failure of partnerships.
Leaders in the industries pointed out that founders believe there is an automatic alignment between different parties simply because everyone has decided to invest in one company. The actual situation is that each party has different expectations about time frame, results, commercialization, risks and more.
In case a business deals with large tech and pharma companies, the issue may worsen.
The following are some key points where the issue of alignment becomes critical for partnership success:
- Product development expectations
- Evidence generation strategies
- Commercialization objectives
- Data ownership and utilization
- Operational strategy
These areas need to be aligned at the early stages of partnerships otherwise things may go wrong despite good technology or markets. ogy or market opportunities.
Protecting Core Strategy While Building Partnerships
The second key lesson discussed at the medtech summit was that of strategic independence.
Experts cautioned companies about letting partnerships determine their product development strategy entirely. Instead, partnerships must help achieve objectives that already exist for the company.
Attendees were advised to develop expertise in the science behind their products. This would help in communicating better with regulators, payors, pharmaceutical firms, and investors.
It was pointed out that internal education is equally vital. Companies operating in one industry only and lacking knowledge in another industry find it challenging to assess opportunities in that industry.
The Future of Cross-Sector Collaboration in Healthcare
These conversations have shown that the collaboration between medtech, big tech, and big pharma will keep increasing as healthcare innovations become increasingly interlinked.
Despite the promising potential, however, partnerships will not be easy; they will entail more than mere investments or common technological goals. There will also be cultural, time, scientific, and communication barriers to overcome.
According to the panel discussion, successful collaborations are based on:
- Transparent communication
- Strategic alignment
- Shared long-term goals
- Understanding of sectoral differences
- Respect for organizational practices
Considering the changes being introduced into the healthcare landscape by artificial intelligence, digital technologies, and innovative treatments, medtech firms can benefit greatly from successful partnerships. Cross-sector medtech partnerships are among the defining conversations at the LSI Asia Summit. Join the founders, investors, and strategists who are building the collaborations that will shape medtech’s next chapter. Learn more at lsiasiasummit.com.
